Compounds > 16-hydroxy-5,8,11,14-eicosatetraenoic acid
Page last updated: 2024-12-08
16-hydroxy-5,8,11,14-eicosatetraenoic acid
Description
16-hydroxy-5,8,11,14-eicosatetraenoic acid (16-HETE) is a bioactive lipid, a type of fatty acid, derived from the metabolism of arachidonic acid. It is a product of the enzyme 15-lipoxygenase (15-LOX) and plays a significant role in various physiological and pathological processes.
**Importance in Research:**
**1. Inflammation and Immune Response:**
* 16-HETE is involved in the regulation of inflammation, acting as a potent anti-inflammatory agent in some studies. It can inhibit the production of pro-inflammatory cytokines like TNF-alpha.
* It is also believed to modulate immune cell function, potentially influencing the activity of macrophages and neutrophils.
**2. Cardiovascular Health:**
* Studies have shown that 16-HETE can influence vascular tone, contributing to blood pressure regulation.
* It may also play a role in platelet aggregation, influencing thrombosis formation.
**3. Cancer Biology:**
* Research suggests that 16-HETE can exhibit both pro- and anti-cancer effects depending on the context.
* It can inhibit tumor growth and induce apoptosis in certain cancer cell lines. However, it can also promote angiogenesis in some tumor types.
**4. Neurological Function:**
* 16-HETE has been implicated in the modulation of neuronal function, including neurotransmission and synaptic plasticity.
* It may have roles in the development of neurological disorders like Alzheimer's disease.
**5. Other Biological Processes:**
* 16-HETE is also involved in regulating cell growth, differentiation, and apoptosis in various tissues.
**Research Focus:**
The wide range of biological activities of 16-HETE makes it a subject of ongoing research interest. Scientists are exploring its potential as a therapeutic target for various diseases, including:
* **Inflammation:** Development of anti-inflammatory drugs.
* **Cardiovascular disease:** Treatment of hypertension, atherosclerosis, and stroke.
* **Cancer:** Prevention and treatment of cancer.
* **Neurological disorders:** Management of Alzheimer's disease and other neurodegenerative conditions.
**Challenges:**
* The precise mechanisms by which 16-HETE exerts its effects are still being elucidated.
* Research is ongoing to determine the optimal therapeutic window and potential side effects associated with targeting 16-HETE pathways.
Overall, 16-HETE is a fascinating bioactive lipid with the potential to significantly impact human health. Further research is needed to unravel its complex biological roles and develop therapeutic applications based on its unique properties.
16-hydroxy-5,8,11,14-eicosatetraenoic acid: arachidonate metabolite in human polymorphonuclear leukocytes [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 182939 |
MeSH ID | M0365694 |
Synonyms (4)
Synonym |
JEKNPVYFNMZRJG-UHFFFAOYSA-N |
16-hydroxyicosa-5,8,11,14-tetraenoic acid |
16-hydroxy-5,8,11,14-eicosatetraenoic acid |
((c)i)16-hete |
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (83.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.34
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.34 (24.57) | Research Supply Index | 1.95 (2.92) | Research Growth Index | 4.29 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |